Skip to content
PubMed This is a summary of 50 peer-reviewed journal articles Updated
Neurology · Spastic Paraplegia 89

Spastic Paraplegia 89 (SPG89): A Patient Guide

At a Glance

SPG89 is an ultra-rare inherited condition caused by AMFR mutations that leads to progressive leg stiffness and weakness. There is no cure yet, but physical therapy, stretching, orthotics, and coordinated rehabilitation can help children maintain movement, comfort, and participation.

Spastic Paraplegia 89 (SPG89) is an ultra-rare genetic condition that primarily affects the way the brain communicates with the muscles in the legs. As a form of Hereditary Spastic Paraplegia (HSP), it is characterized by spasticity—a persistent stiffness and tightness in the lower limbs—alongside muscle weakness. This occurs because of mutations in the AMFR gene, which disrupt the internal health of the long nerves that control movement. Because it is inherited in an autosomal recessive manner, a child typically inherits a mutated copy of the gene from each parent, who are usually unaffected carriers themselves [1].

The way SPG89 behaves can vary significantly from one child to another, and because the condition is so rare, it is incompletely characterized. In its “pure” clinical presentation, the symptoms are mostly limited to the legs, affecting a child’s gait and balance. In “complex” presentations, the condition may also involve developmental delays or mild learning challenges. While SPG89 is a progressive condition, meaning the stiffness can increase over time, the exact rate of progression and long-term outcomes for an individual child cannot be reliably predicted from the diagnosis alone [2]. Understanding the specific genetic nature of your child’s condition through definitive testing is a vital first step, as it allows your medical team to move past the “diagnostic odyssey” and focus on a targeted care plan [3].

Living with SPG89 is a journey of proactive management and adaptation. Because there is currently no cure for the underlying genetic mutation, the goal of treatment is to manage symptoms and maximize your child’s physical function and comfort. This is best achieved through a multidisciplinary care team—a group of specialists including neurologists, physical therapists, and rehabilitation doctors who work together to support every aspect of your child’s development [4]. Regular, individualized physical therapy, consistent stretching, and the use of supportive tools like orthotics are the cornerstones of maintaining mobility and preventing complications [5].

What is Known and What is Still Uncertain

  • Known: SPG89 is caused by mutations in the AMFR gene and causes progressive spasticity and weakness.
  • Uncertain: The adult outcomes, exact rate of progression, and frequency of specific symptoms are not fully established due to the small number of reported cases globally.
  • Known: Physical therapy and rehabilitation can improve function, comfort, and participation in daily life.
  • Uncertain: There is currently no established disease-modifying therapy that stops the genetic progression.

While a diagnosis of such a rare condition can feel overwhelming, it also provides a roadmap for support. By focusing on symptomatic care and staying connected with a dedicated team of experts, you can play a central role in protecting your child’s quality of life. Research into the AMFR gene and its role in the nervous system is ongoing, and every child’s story contributes to a growing global understanding of this condition [1]. Your family is not just navigating a diagnosis; you are part of a small but dedicated community working toward a future of better support and clearer answers.

Important Safety Note: Sudden loss of strength, rapid regression of skills, fever with urinary symptoms, inability to urinate, or severe new pain are not typical slow progression and require prompt medical attention.

Common questions in this guide

What causes SPG89, and how is it passed from parents to children?
SPG89 results from changes in both copies of the AMFR gene. A child usually inherits one changed copy from each parent, while the parents are unaffected carriers. Genetic testing can confirm the specific changes involved.
What symptoms might a child with SPG89 develop?
Children commonly have stiffness and weakness in the legs, which can affect walking, gait, and balance. Some children have a mainly leg-related form, while others may also experience developmental delays or mild learning difficulties.
Does SPG89 get worse over time, and can doctors predict my child’s future?
SPG89 is considered progressive, so leg stiffness may increase over time. However, the rate of change and long-term outlook vary widely, and adult outcomes are not yet well established because so few cases are known.
Is there a cure or treatment that stops SPG89?
There is currently no cure for the underlying AMFR-related genetic change and no established treatment that stops the disease process. Care focuses on symptoms and function, including physical therapy, stretching, orthotics, and coordinated rehabilitation.
How can physical therapy help a child with SPG89?
An individualized physical therapy program can support movement, comfort, participation, and independence. Stretching and supportive devices such as orthotics may help maintain mobility and reduce complications, with goals adjusted as the child’s needs change.
When should I seek urgent medical help for a child with SPG89?
Sudden loss of strength, rapid loss of previously learned skills, fever with urinary symptoms, inability to urinate, or severe new pain should receive prompt medical attention. These changes are not typical of the condition’s usual slow progression.

Get notified when new evidence is published on spastic paraplegia 89, autosomal recessive.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (5)
  1. 1

    AMFR dysfunction causes autosomal recessive spastic paraplegia in human that is amenable to statin treatment in a preclinical model.

    Deng R, Medico-Salsench E, Nikoncuk A, et al.

    Acta neuropathologica 2023; (146(2)):353-368 doi:10.1007/s00401-023-02579-9.

    PMID: 37119330
  2. 2

    Childhood-onset hereditary spastic paraplegia: at the crossroads between neurodevelopment and neurodegeneration.

    Espasandin-Hueter N, Salazar-Villacorta A, Escudero JM, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2026; (65()):50-65 doi:10.1016/j.ejpn.2026.10.002.

    PMID: 42976539
  3. 3

    Increased Diagnostic Yield of Spastic Paraplegia with or Without Cerebellar Ataxia Through Whole-Genome Sequencing.

    Kim A, Kumar KR, Davis RL, et al.

    Cerebellum (London, England) 2019; (18(4)):781-790 doi:10.1007/s12311-019-01038-0.

    PMID: 31104286
  4. 4

    French guidelines for the diagnosis and management of pure hereditary spastic paraplegia.

    Mania-Pâris L, Ewenczyk C, Nicolas G, et al.

    Revue neurologique 2025; (181(6)):471-482 doi:10.1016/j.neurol.2025.05.001.

    PMID: 40450402
  5. 5

    The therapeutic effects of physical treatment for patients with hereditary spastic paraplegia: a narrative review.

    Di Ludovico A, Ciarelli F, La Bella S, et al.

    Frontiers in neurology 2023; (14()):1292527 doi:10.3389/fneur.2023.1292527.

    PMID: 38093754

This SPG89 guide is for educational purposes and does not replace medical advice. A neurologist, geneticist, or rehabilitation team can interpret your child’s symptoms and create an individualized care plan.